structured treadmill walking
BehavioralThree doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
NCT Number: NCT05789485
The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut, United States
Study staff will also confirm remote training feasibility including items such as access to Wi-Fi and a treadmill for the study duration. If patients do not have access to a treadmill, ExOnc staff may coordinate access to a fitness facility local to the participant, to facilitate treadmill access for the study duration. Fitness facility access will be provided through Wellhub, a service that allows use of nearby gyms and studios through a single app-based solution.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment.
Time frame: 5 years
RDI (%) will be calculated as the ratio of delivered to planned dose intensity (delivered dose intensity/planned dose intensity).
Contact information is provided by the study sponsor or research team.
Memorial Sloan Kettering Cancer Center
Other
Dose-response of Aerobic Training During Chemotherapy for Gastrointestinal Cancers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05131815
Astrocytoma, Behavior
Los Angeles, California, United States
View Trial DetailsNCT04131426
Behavior, Body Weight
Rochester, New York, United States
View Trial DetailsNCT04802486
Behavior, Body Weight
Rochester, New York, United States
View Trial DetailsNCT06596694
Digestive System Diseases, Digestive System Neoplasms
Santa Monica, California, United States
View Trial Details